Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.
Also called NCT01214239
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 300 participants
- Registry
-
NCT01214239
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- China, Malaysia, Philippines
- Registry status
- Completed
Technical summary
Registry record NCT01214239. Randomized; double masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2012-05 (actual). Results posted on 2013-07-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Linagliptin
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct01214239- Content hash
cbb29eeae4f67bbf135b79b6fd1f248d439d48f8b444a7acf41a43ca70dc0d4c